ghk-cu hair growth study GHK Peptide Clinical Trial (2016) — Research Summary ghk-cu hair growth clinical study

Permeation experiment was carried out for 24 h at 37 C with Franz-type diffusion cells

Clin Med (Lond)

Clinical trial data for FDA-approved GLP-1 receptor agonists demonstrates: Significant weight reduction: Meaningful mean body weight reduction in trial participants (see FDA-approved labeling for specific approved products) Cardiorenal protection: Reduced risk of major adverse cardiovascular events and kidney disease progression Improved lipid profiles: Decreased triglycerides and increased HDL cholesterol Blood pressure reduction: Modest but clinically significant decreases in systolic blood pressure Reduced inflammation: Decreased inflammatory markers associated with metabolic syndrome Note: Clinical outcomes cited above reflect published trial data for FDA-approved GLP-1 receptor agonists

may vary elsewhere

It establishes a clear baseline and is the easiest to replicate